Pulmonary hemorrhage after percutaneous coronary intervention with abciximab therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12479522.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Abciximab has a key role in the treatment of patients with acute coronary syndromes undergoing percutaneous coronary intervention; however, an increased risk of bleeding complications is well recognized. We report a case of serious pulmonary hemorrhage after use of abciximab therapy. A definitive indication and treatment guideline should be available to minimize serious bleeding complications. Additionally, respiratory symptoms should be monitored closely for early detection of serious pulmonary hemorrhage in patients receiving abciximab therapy during percutaneous coronary intervention.
Medical subject headings
- Antibodies, Monoclonal
- Hemorrhage
- Immunoglobulin Fab Fragments
- Lung Diseases
- Platelet Glycoprotein GPIIb-IIIa Complex